Despite Utility, NGS Testing for Cancer Often Denied Insurance Coverage
Expanded genomic panel testing was clinically impactful in nearly two-third of patients with high-risk cancer, yet payers reimbursed only 10.75% of the charge on average, if reimbursed at all, according to findings from a recent study.
ICER Issues Recommendations on Fair Drug Coverage
In a new white paper, ICER released key guidance addressing cost sharing, eligibility criteria, step therapy policies, and prescriber restrictions for insurance coverage policies that affect patient access to prescription drugs.
Improving Patient Education Reduces Overtreatment of Breast Cancer
Improving patient education and emphasizing the favorable prognosis directing national recommendations for de-escalation may reduce breast cancer overtreatment in women aged 60 years and older.
Targeted Gene Testing-Directed Treatment Cost Effective for Metastatic GIST
Study findings support the cost-effectiveness of widespread adoption of genetic testing for patients with newly diagnosed metastatic GIST.
Electronic System Allows Patients to Self-Report Adverse Events From Cancer Treatment
Patients receiving cancer treatment who used a computer or phone to self-report adverse events and quality of life information found the electronic, home-based system feasible and acceptable.
Rituximab and Trastuzumab Biosimilars Yield Acceptable Safety in Real- World Setting
Biosimilar rituximab and biosimilar trastuzumab are associated with acceptable safety profiles among patients with cancer treated in the real-world clinical setting, according to a recent study.
Genetic counseling and testing offered by a patient’s oncologist was feasible and deemed satisfactory by clinicians and patients with metastatic prostate cancer.
Feasibility of Electronic PROs During Radiotherapy for Head and Neck Cancer
Findings from a recent analysis show the collection of electronic PROs during radiotherapy is feasible for patients with head and neck cancer undergoing treatment.
